RESUMO
BACKGROUND: Pain is undertreated in older populations. At the same time, increased use of opioids is of concern in the Western world. AIMS: We sought to analyze temporal trends in musculoskeletal pain and prescribed analgesic treatment among community-dwelling people aged 75-95 years using cross-sectional cohort data spanning 20 years. METHODS: The Helsinki Aging Study recruited random samples of people aged 75, 80, 85, 90, and 95 years in 1999, 2009, and 2019. In total, 5707 community-dwelling persons participated in the study. The participants reported their medical diagnoses, regular prescription medications, and the presence of back pain or joint pain within the last 2 weeks (never, sometimes, or daily). We compared analgesic use among participants reporting and not reporting musculoskeletal pain in 1999, 2009, and 2019. RESULTS: Of the participants, 57-61% reported intermittent or daily musculoskeletal pain. The percentage receiving a prescribed daily analgesic increased from 9% in 1999 to 16% in 2019. The use of non-steroidal anti-inflammatory drugs (NSAIDs) decreased from 1999 to 2019, while the use of paracetamol increased from 2 to 11%. Opioids were taken by 2% in 1999 and 3% in 2019. Of those reporting daily musculoskeletal pain, 20%, 35%, and 32% received regular pain medication in 1999, 2009, and 2019, respectively. CONCLUSIONS: Pain remains undertreated in the community-dwelling older population, although the use of regular prescribed analgesics increased between 1999 and 2019. The use of NSAIDs has decreased, while the use of paracetamol has increased. Daily opioid use has remained modest.
Assuntos
Dor Musculoesquelética , Idoso , Analgésicos/uso terapêutico , Estudos Transversais , Humanos , Vida Independente , Dor Musculoesquelética/tratamento farmacológico , Dor Musculoesquelética/epidemiologia , PrevalênciaRESUMO
BACKGROUND: There is an unmet clinical need for a cat-specific formulation of amlodipine to treat hypertensive cats. OBJECTIVES: To assess the efficacy of chewable amlodipine tablets in reducing systolic blood pressure (SBP) in cats diagnosed with systemic arterial hypertension. ANIMALS: Seventy-seven client-owned cats with systemic hypertension were included (median age 14 years). METHODS: The study was randomized, double-blinded, and placebo-controlled. Forty-two cats received 0.125-0.50 mg/kg amlodipine once daily for 28 days; 35 cats received placebo. After 28 days all cats continued with amlodipine for 2-3 months in an open-label phase. Blood pressure was measured using high definition oscillometry. A responder was defined as a cat showing a decrease of SBP to <150 mmHg at 28 days or a decrease from baseline ≥15%. RESULTS: Sixty-one cats completed the study. The responder rate was 63% in amlodipine group and 18% in placebo group. Cats receiving amlodipine were 7.9 (95% CI 2.6-24.1) times more likely to be classified as responders when compared to those receiving placebo (P < .001). From a mean (±SD) baseline value of 181 (±12) mmHg, SBP decreased to 154 (±17) mmHg with amlodipine and to 170 (±21) mmHg with placebo (P < .001). The voluntary acceptance rate of amlodipine formulation was 73%. CONCLUSIONS AND CLINICAL IMPORTANCE: The chewable amlodipine tablet effectively reduced SBP compared with placebo in hypertensive cats, and was well-tolerated. It can be used concomitantly with angiotensin-converting enzyme inhibitors and in cats with chronic kidney disease.
Assuntos
Anlodipino/uso terapêutico , Anti-Hipertensivos/uso terapêutico , Doenças do Gato/tratamento farmacológico , Hipertensão/veterinária , Administração Oral , Anlodipino/administração & dosagem , Animais , Anti-Hipertensivos/administração & dosagem , Gatos , Método Duplo-Cego , Feminino , Hipertensão/tratamento farmacológico , Hipertensão/prevenção & controle , Masculino , ComprimidosRESUMO
Accurate information on changes in small intestinal microflora in dogs is rather limited because of difficulties in obtaining samples of small intestinal chyme. In the study reported here, intussuscepted nipple valves were surgically placed into the jejunum of seven laboratory beagles to obtain intestinal juice samples. The influence of the fistula on intestinal motility was determined by use of barium-impregnated polyethylene spheres (BIPS) and on microflora by use of bacterial culturing. The BIPS were fed two weeks before surgery and again five weeks after surgery. Bacterial samples were collected before (fecal samples), during (small intestinal samples) and 11 weeks after surgery. There were no surgical complications, and the animals tolerated the fistula well. Mean orocolic transit percentage was 93% before and 83% after surgery, and notable changes in gastrointestinal motility were not seen, except in one dog. The surgery did not markedly alter the bacterial flora in feces. Microflora did change in small intestinal samples; however, methodologic factors may explain most of these differences. In conclusion, the nipple valve is a promising method that creates easy and safe long-term access to the jejunum and appears not to have an influence on intestinal function.